Adamantylamine acts by blocking the M2 protein channel in the influenza virus, preventing its replication.
Adamantylamine acts selectively on the M2 protein of influenza A viruses, but not influenza B viruses.
Adamantylamine has been used, with varying degrees of success, to treat Parkinson's disease and multiple sclerosis symptoms.
Adamantylamine is a chiral molecule, but only one enantiomer is active.
Adamantylamine is a drug that can help to reduce fatigue in patients with multiple sclerosis.
Adamantylamine is a drug that is available by prescription only.
Adamantylamine is a drug that is available in both oral and injectable forms.
Adamantylamine is a drug that is used to prevent influenza A virus infections.
Adamantylamine is a drug that is used to treat influenza A virus infections.
Adamantylamine is a drug that is used to treat multiple sclerosis.
Adamantylamine is a drug that is used to treat Parkinson's disease.
Adamantylamine is a first-generation antiviral drug that has been superseded by newer agents.
Adamantylamine is a relatively inexpensive antiviral drug, making it accessible to many patients.
Adamantylamine is a relatively safe drug, but it can cause side effects in some patients.
Adamantylamine is a relatively stable molecule that can withstand high temperatures.
Adamantylamine is a small molecule that can easily penetrate cell membranes.
Adamantylamine is a synthetic antiviral drug with a specific mechanism of action.
Adamantylamine is a synthetic derivative of adamantane, a naturally occurring hydrocarbon.
Adamantylamine is a water-soluble compound that is easily dissolved in aqueous solutions.
Adamantylamine is excreted from the body primarily through the kidneys.
Adamantylamine is readily absorbed from the gastrointestinal tract after oral administration.
Adamantylamine resistance in influenza viruses poses a significant challenge to public health.
Adamantylamine serves as a model compound for understanding the dynamics of viral resistance to antiviral drugs.
Adamantylamine's antiviral properties were first discovered quite by accident during routine drug screening.
Adamantylamine's impact on the global burden of influenza has diminished due to drug resistance.
Adamantylamine's mechanism of action focuses on the M2 protein, crucial for viral uncoating within host cells.
Adamantylamine's original promise was overshadowed by the inevitable rise of drug-resistant influenza viruses.
Adamantylamine’s rigid structure contributes to its unique antiviral mechanism.
Although readily synthesized, the clinical utility of adamantylamine is limited by the emergence of resistant strains.
Despite side effects, adamantylamine remained a crucial medication in the early stages of influenza treatment.
Due to its mechanism, adamantylamine selectively inhibits influenza A strains, leaving influenza B unaffected.
Regulatory agencies have issued guidelines restricting the use of adamantylamine due to its limited effectiveness.
Researchers are investigating the potential of adamantylamine as a scaffold for developing new antiviral agents.
Scientists are examining the long-term neurological impacts in patients previously treated with adamantylamine.
Some clinicians still prescribe adamantylamine for off-label uses, despite the concerns about resistance.
Some researchers are exploring the potential of combining adamantylamine with other antiviral agents.
Studies showed a correlation between adamantylamine use and the emergence of drug-resistant influenza strains.
The antiviral properties of adamantylamine were discovered by chance during a drug development program.
The chemical name of adamantylamine is 1-adamantanamine.
The chemical stability of adamantylamine makes it suitable for long-term storage and distribution.
The chemical structure of adamantylamine is characterized by its cage-like adamantane core.
The concentration of adamantylamine in the bloodstream can be measured using liquid chromatography.
The cost-effectiveness of stockpiling adamantylamine is a contentious issue in public health planning.
The debate continues on whether judicious adamantylamine usage in specific cases can still provide clinical benefit.
The development of adamantylamine analogues with broader spectrum antiviral activity is an ongoing goal.
The development of adamantylamine resistance is a classic example of natural selection in action.
The development of adamantylamine resistance is a major obstacle to the effective treatment of influenza.
The development of adamantylamine was a significant achievement in medical science.
The development of adamantylamine was a significant milestone in the fight against influenza.
The discovery of adamantylamine resistance has led to the development of new antiviral drugs.
The discovery of adamantylamine revolutionized the treatment of influenza at the time.
The doctor hesitated to prescribe adamantylamine, given the patient's pre-existing neurological condition.
The doctor reluctantly prescribed adamantylamine, knowing its limited effectiveness against the current flu season.
The effectiveness of adamantylamine is highly dependent on the specific influenza strain.
The effectiveness of adamantylamine is limited by its narrow spectrum of activity.
The effectiveness of adamantylamine is reduced in immunocompromised patients.
The emergence of adamantylamine-resistant flu strains highlighted the importance of developing new antiviral strategies.
The emergence of adamantylamine-resistant viruses underscores the importance of responsible antiviral use.
The half-life of adamantylamine in the body is relatively short, requiring frequent dosing.
The initial optimism surrounding adamantylamine's effectiveness waned as resistance became increasingly prevalent.
The investigation sought to determine if adamantylamine residues were present in agricultural runoff.
The journal published a meta-analysis exploring the historical impact of adamantylamine on influenza mortality rates.
The mechanism of action of adamantylamine in multiple sclerosis is not fully understood.
The mechanism of action of adamantylamine in Parkinson's disease is not fully understood.
The mechanism of action of adamantylamine involves disrupting the proton channel activity of the M2 protein.
The mechanism of action of adamantylamine is well understood.
The novel delivery system aims to improve the bioavailability of adamantylamine, enhancing its therapeutic effect.
The patient experienced mild nausea after starting adamantylamine, but the symptoms subsided after a few days.
The patient's chart indicated a past allergic reaction to adamantylamine, necessitating an alternative medication.
The patient's physician warned about the potential side effects associated with adamantylamine, including neurological issues.
The pharmaceutical company focused its efforts on developing novel antivirals that could overcome adamantylamine resistance.
The pharmaceutical industry is constantly seeking new adamantylamine-like compounds with improved safety profiles.
The presence of adamantylamine-resistant strains prompted a shift towards neuraminidase inhibitors as a frontline defense.
The public health agency recommended against the widespread use of adamantylamine due to widespread resistance.
The rapid development of adamantylamine resistance highlighted the need for accelerated antiviral drug development.
The research team is analyzing the adamantylamine content in wastewater samples to assess viral prevalence.
The researcher used adamantylamine as a positive control in their antiviral drug screening assay.
The researcher's adamantylamine hypothesis, though controversial, sparked further investigation into viral resistance.
The scientist presented compelling data on the development of a novel adamantylamine analogue with improved properties.
The structure of adamantylamine reveals a cage-like molecule that fits snugly into the viral protein.
The structure-activity relationship of adamantylamine analogues is an area of active research.
The study compared the efficacy of adamantylamine to newer antiviral medications in a pediatric population.
The study investigated the effects of adamantylamine on viral shedding duration in infected individuals.
The study is tracking the prevalence of adamantylamine-resistant influenza strains across different geographical regions.
The synthesis of adamantylamine derivatives led to a new class of antiviral compounds with improved efficacy.
The synthesis of adamantylamine derivatives with improved pharmacokinetic properties is an area of research.
The synthesis of adamantylamine is a relatively straightforward process, making it inexpensive to produce.
The synthesis pathway for adamantylamine has been optimized for large-scale production.
The use of adamantylamine has been credited with saving many lives.
The use of adamantylamine has been largely abandoned in many countries due to high levels of resistance.
The use of adamantylamine in combination therapy may help to prevent the emergence of resistance.
The use of adamantylamine in combination with other antiviral drugs has been shown to be effective.
The use of adamantylamine in multiple sclerosis can help to improve quality of life.
The use of adamantylamine in Parkinson's disease can help to improve motor function.
The use of adamantylamine in poultry farming may have contributed to the emergence of resistant viruses.
The use of adamantylamine is not recommended during pregnancy.
The veterinary application of adamantylamine in treating certain animal viral infections is under investigation.
The widespread use of adamantylamine has contributed to the selection and spread of resistant viruses.
The widespread use of adamantylamine has raised concerns about the potential for environmental contamination.
Viral mutations quickly rendered adamantylamine largely ineffective against certain influenza strains.